Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

Effect of Simvastatin in Serum Interleukin-6 Level in Patients with Acute Ischemic Stroke

Folia Medica Indonesiana · Vol. 56 No. 3 (2020) · pp. 165–165

DOI
10.20473/fmi.v56i3.24508
ISSN
2355-8393, 2599-056X
Published
2020-09-23
Publisher
Airlangga University
Language
en
License
creativecommons.org/licenses/by-nc-sa/4.0/

Abstract

Acute ischemic stroke is the leading cause of death and causing permanent disability in adults worldwide. In acute ischemic stroke, IL-6 levels positively correlated to more severe neurological deficits, more extensive brain damage and worse prognoses. The use of statin was associated with milder initial stroke severity, better functional outcome and lower mortality. This clinically randomized controlled trial study was aimed to analyze the serum levels of IL 6 in acute ischemic stroke patients who treated with Simvastatin 20 mg compare to placebo. Samples were taken using consecutive sampling method from hospitalized acute ischemic stroke patients in Neurology Department of Dr. Soetomo Teaching Hospital Surabaya and Airlangga University Hospital Surabayafrom August to November 2017. Total of 44 patients met the inclusion criteria, consisting of 22 patients in treatment group and 22 patients in control group.There were no significant difference in the characteristic of the patients in both groups (p>0.05). Averages of serum IL-6 in the control and the treatment group are 38.594±74.313 and 17.760±25.253(p=0,438) while averages of serum IL-6 post in the control group and the treatment are 46.586±103.484 and 15.275±17.183 (p=0,589). There were no significant level escalation in pre and post of control group (p = 0.205) and also no significant level reduction in pre and post of treatment group (p = 0.411), while the average difference in the control group (-7.992 + 78.912 pg/ml) and in the treatment group (2.485 + 23.738 pg/ml).

Keywords

Collaboration network of the authors

40 authors · 100 co-authorship links · 25 across different organisations · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • Rumah Sakit Dokter Soetomo
  • Universitas Hang Tuah
  • Seoul National University
  • Diponegoro University
  • Sebelas Maret University
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Yulistiani YulistianiUniversitas Airlangga2
Kuntaman KuntamanUniversitas Airlangga2
Djoko Agus SupraptoUniversitas Airlangga1
Anny HanifahUniversitas Hang Tuah1
Isti SuharjantiUniversitas Airlangga1
Jakfar ShodiqAffiliation unknown1
M Fata FatihuddinUniversitas Airlangga1
Beom Joon KimSeoul National University1
Azizah Amimathul FirdhaAffiliation unknown1
Nur HadiyantiUniversitas Airlangga1
Mohammad Saiful IslamUniversitas Airlangga1
Binti MuzayyanahUniversitas Airlangga1
Nuraida WisudaniAffiliation unknown1
Umul FadlilahUniversitas Airlangga1
Yudi Agung WibisonoAffiliation unknown1
Mia MelindaUniversitas Airlangga1
Dhita Evi AryaniUniversitas Airlangga1
Nun ZairinaRumah Sakit Dokter Soetomo1
Landia SetiawanRumah Sakit Dokter Soetomo1
Asra Al FauziUniversitas Airlangga1
Christrijogo Sumartono WaloejoUniversitas Airlangga1
Muhammad Jafar ShodiqUniversitas Airlangga1
Ana Nurlaili HidayahUniversitas Airlangga1
Muqoddar ThayyibAffiliation unknown1
Retnaningsih RetnaningsihDiponegoro University1
Baarid Luqman HamidiSebelas Maret University1
Mohammad Fathul QoribUniversitas Airlangga1
Ayu Imamatun NisaUniversitas Airlangga1
Arlia Ayu DamayantiUniversitas Airlangga1
Jeffri NagasastraUniversitas Airlangga1
Rino WahyudiAffiliation unknown1
Ruhaya FitrinaAffiliation unknown1
Khairil ArmalUniversitas Airlangga1
Diny PuspitasariUniversitas Airlangga1
Taufiqur RahmanUniversitas Airlangga1
Usman HadiUniversitas Airlangga1
Nurul Ma'rifahUniversitas Airlangga1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Effect of Simvastatin in Serum Interleukin-6 Level in Patients with Acute Ischemic Stroke</dc:title><dc:creator>Maria Lettisia Meo</dc:creator><dc:creator>Abdulloh Machin</dc:creator><dc:creator>Didik Hasmono</dc:creator><dc:subject>simvastatin</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>acute ischemic stroke</dc:subject><dc:subject>statins</dc:subject><dc:subject>serum cytokine levels</dc:subject><dc:subject>neuroinflammation</dc:subject><dc:subject>stroke severity</dc:subject><dc:subject>functional outcome</dc:subject><dc:description xml:lang="en">Acute ischemic stroke is the leading cause of death and causing permanent disability in adults worldwide. In acute ischemic stroke, IL-6 levels positively correlated to more severe neurological deficits, more extensive brain damage and worse prognoses. The use of statin was associated with milder initial stroke severity, better functional outcome and lower mortality. This clinically randomized controlled trial study was aimed to analyze the serum levels of IL 6 in acute ischemic stroke patients who treated with Simvastatin 20 mg compare to placebo. Samples were taken using consecutive sampling method from hospitalized acute ischemic stroke patients in Neurology Department of Dr. Soetomo Teaching Hospital Surabaya and Airlangga University Hospital Surabayafrom August to November 2017. Total of 44 patients met the inclusion criteria, consisting of 22 patients in treatment group and 22 patients in control group.There were no significant difference in the characteristic of the patients in both groups (p&gt;0.05). Averages of serum IL-6 in the control and the treatment group are 38.594±74.313 and 17.760±25.253(p=0,438) while averages of serum IL-6 post in the control group and the treatment are 46.586±103.484 and 15.275±17.183 (p=0,589). There were no significant level escalation in pre and post of control group (p = 0.205) and also no significant level reduction in pre and post of treatment group (p = 0.411), while the average difference in the control group (-7.992 + 78.912 pg/ml) and in the treatment group (2.485 + 23.738 pg/ml).</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2020-09-23</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v56i3.24508</dc:identifier><dc:identifier>10.20473/fmi.v56i3.24508</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 56 No 3 (2020); 165-165</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/24508/13275</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>